Oral HER2-targeted Therapy Zongertinib Demonstrates Clinical Benefit in Advanced HER2-mutated Lung Cancer
April 28, 2025
April 28, 2025
PHILADELPHIA, Pennsylvania, April 28 [Category: Medical] -- The American Association for Cancer Research posted the following news release:
* * *
Oral HER2-targeted Therapy Zongertinib Demonstrates Clinical Benefit in Advanced HER2-mutated Lung Cancer
CHICAGO - Zongertinib, a human epidermal growth factor receptor 2 (HER2)-targeted tyrosine kinase inhibitor, elicited durable responses in patients with advanced, previously treated non-small cell lung cancer . . .
* * *
Oral HER2-targeted Therapy Zongertinib Demonstrates Clinical Benefit in Advanced HER2-mutated Lung Cancer
CHICAGO - Zongertinib, a human epidermal growth factor receptor 2 (HER2)-targeted tyrosine kinase inhibitor, elicited durable responses in patients with advanced, previously treated non-small cell lung cancer . . .